What is your general approach to treatment sequencing of available regimens in castration-resistant metastatic prostate cancer?

For mCRPC, my general approach with standard agents is a next-generation AR agent (typically started in the CSPC setting), followed by docetaxel, followed by Lu-PSMA. If disease is progressing slowly and is PSA producing, I will consider a switch from a first-line to a second-line hormonal agent, ty...